Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy
Michael J. Struharik(Solidus Biosciences (United States)), Xiaoqing Pan, Brittany A. Fickau(Medical College of Wisconsin), Thomas J. Conlon(University of Florida), Michael W. Lawlor(Medical College of Wisconsin), Diane Golebiowski(University of Massachusetts Chan Medical School), Carl H. Shanks, Joel Schneider(Solidus Biosciences (United States)), Eleanor C. Hawkins(North Carolina State University), Cindy Balog‐Alvarez, Margaret Beatka(Medical College of Wisconsin), Kristy J. Brown(Children's National), Jeffrey S. Chamberlain(University of Washington), Hui Meng(Medical College of Wisconsin), Joe N. Kornegay(Texas A&M University), Martin Styner(University of North Carolina at Chapel Hill), Kirsten E. Coleman(University of Florida), Stephen D. Hauschka(University of Washington), Amanda K. Bettis(Texas A&M University), Julie M. Crudele(University of Washington), Dongsheng Duan(University of Missouri), Barry J. Byrne(University of Florida), Carl Morris(Sylvana Research), Sharla M. Birch(Texas A&M University), Lee‐Jae Guo(Texas A&M University), Paul Nghiem(Fred Hutch Cancer Center), Mihye Ahn(University of Nevada, Reno), Juan Carlos Prieto(University of Chile), Nathalie Clément(University of Florida), Joraima González, Manuela Corti(University of Florida)
Cited by 0
Related Papers
Duchenne muscular dystrophy
|Nature Reviews Disease Primers|2021|1.2k
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
|Science|2015|1.1k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
|Nature Medicine|2004|611
High levels of AAV vector integration into CRISPR-induced DNA breaks
|Nature Communications|2019|430